Shares of Moderna Inc. MRNA, +1.97% were up 2.5% in trading on Monday afternoon after the Wall Street Journal reported that the company is considering pricing its COVID-19 vaccine at $110 to $130 per dose. That’s the same price range that Pfizer Inc. PFE, -5.04% and BioNTech BNTX, -0.64% suggested for their COVID vaccine once the COVID vaccines move into a commercial market. They are currently purchased and distributed by the U.S. government. Moderna’s stock is down 13.4% over the past year, while the broader S&P 500 SPX, -0.02% has declined 17.0%.
This article was originally published by Marketwatch.com. Read the original article here.
